Key result
The Hospital Readmissions Reduction Program was associated with a statistically significant overall reduction in 30-day readmission rates for targeted conditions, with a 0.8 percentage point greater decline among Medicare patients compared to those with non-targeted conditions.
Why the study?
Although studies examined the overall impacts of the Hospital Readmissions Reduction Program, research was limited regarding its effects across different vulnerable populations.
Does the Hospital Readmissions Reduction Program (HRRP) reduce 30-day readmissions in vulnerable populations with acute myocardial infarction, heart failure, and pneumonia?
Observational (n=34,000,000)
Yes
Does the Hospital Readmissions Reduction Program (HRRP) reduce 30-day readmissions in vulnerable populations with acute myocardial infarction, heart failure, and pneumonia?
Mean Difference: -0.008
p-value: p=<0.01
The HRRP successfully reduced 30-day readmissions for targeted conditions like AMI and HF, including among vulnerable populations, though disparities in readmission rates remain.
No takes yet. Share an insight, caveat, or question.
Supports HRRP incentives for targeted conditions in vulnerable populations; leaves open whether disparities can be eliminated.
Gai et al. (2019) conducted an observational in Acute myocardial infarction, heart failure, and pneumonia (n=34,000,000). Hospital Readmissions Reduction Program (HRRP) vs. Pre-HRRP period and non-targeted conditions (GI) or privately insured patients was evaluated on 30-day hospital readmission for HRRP-targeted conditions (Difference-in-Difference -0.008, p=<0.01). The Hospital Readmissions Reduction Program was associated with a statistically significant overall reduction in 30-day readmission rates for targeted conditions, with a 0.8 percentage point greater decline among Medicare patients compared to those with non-targeted conditions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: